IP Library Granted Patent US 8,158,820
Granted Patent B2
US 8,158,820 · App. 10/551,783 · Granted Apr 17, 2012

Compounds

Assignee: AstraZeneca AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,158,820
App. No.
10/551,783
Granted
Apr 17, 2012
Kind
B2
Abstract

The invention relates to substituted phenoxyacetic acids (I) as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.

Claims (162)

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:

in which:

X is halogen, cyano, nitro, S(O) n R 6 (wherein n is 0, 1 or 2) or C 1-4 -alkyl which is substituted by one or more halogen atoms;

Y is hydrogen;

Z is phenyl or naphthyl each of which is substituted by one or more substituents independently selected from halogen, CN, OH, SH, nitro, COR 9 , CO 2 R 6 , SO 2 R 9 , OR 9 , SR 9 , SOR 9 , SO 2 NR 10 R 11 , CONR 10 R 11 , NR 10 R 11 , NHSO 2 R 9 , NR 9 SO 2 R 9 , NR 6 CO 2 R 6 , NHCOR 9 , NR 9 COR 9 , NR 6 CONR 4 R 5 , NR 6 SO 2 NR 4 R 5 , aryl, heteroaryl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl or C 1-6 alkyl, the latter four groups being optionally substituted by one or more substituents independently selected from halogen, C 3 -C 7 cycloalkyl, OR 6 , NR 6 R 7 , S(O) n R 6 (wherein n is 0, 1 or 2), CONR 6 R 7 , NR 6 COR 7 , SO 2 NR 6 R 7 and NR 6 SO 2 R 7 ;

R 1 and R 2 independently represent a hydrogen atom, halogen, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 7 cycloalkyl or a C 1-6 alkyl group, the latter four groups being optionally substituted by one or more substituents independently selected from halogen,

C 3 -C 7 cycloalkyl, NR 6 R 7 , OR 6 , S(O) n R 6 (wherein n is 0, 1 or 2);

or

R 1 and R 2 together can form a 3-8 membered ring optionally containing one or more atoms selected from O, S, NR 6 and itself optionally substituted by one or more C 1 -C 3 alkyl or halogen;

R 3 represents C 3 -C 7 cycloalkyl or C 1-6 alkyl which may be optionally substituted by one or more substituents independently selected from halogen, C 3 -C 7 cycloalkyl, OR 6 and NR 6 R 7 , S(O) n R 6 (wherein n is 0, 1 or 2), CONR 6 R 7 , NR 6 COR 7 , SO 2 NR 6 R 7 and NR 6 SO 2 R 7 ;

R 4 and R 5 independently represent hydrogen, C 3 -C 7 cycloalkyl or C 1-6 alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C 3 -C 7 cycloalkyl, OR 6 and NR 6 R 7 , S(O) n R 6 (wherein n is 0, 1 or 2), CONR 6 R 7 , NR 6 COR 7 , SO 2 NR 6 R 7 and NR 6 SO 2 R 7 ;

or

R 4 and R 5 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocylic ring optionally containing one or more atoms selected from 0, S(O) n (wherein n is 0, 1 or 2), NR 8 , and itself optionally substituted by halogen or C 1-3 alkyl;

R 6 and R 7 independently represents a hydrogen atom or C 1 -C 6 alkyl;

R 8 is hydrogen, C 1-4 alkyl, —COC 1 -C 4 alkyl, CO 2 C 1 -C 4 alkyl or CONR 6 C 1 -C 4 alkyl;

R 9 represents aryl, heteroaryl, C 3 -C 7 cycloalkyl or C 1-6 alkyl, the latter two groups may be optionally substituted by one or more substituents independently selected from halogen, C 3 -C 7 cycloalkyl, aryl, heteroaryl OR 6 and NR 6 R 7 , S(O) n R 6 (wherein n is 0, 1 or 2), CONR 6 R 7 , NR 6 COR 7 , SO 2 NR 6 R 7 and NR 6 SO 2 R 7 ;

R 10 and R 11 independently represent aryl or heteroaryl, hydrogen, C 3 -C 7 cycloalkyl or C 1-6 alkyl, the latter two groups being optionally substituted by one or more substituents independently selected from halogen, C 3 -C 7 cycloalkyl, aryl, heteroaryl, OR 6 and NR 6 R 7 , S(O) n R 6 (wherein n is 0, 1 or 2), CONR 6 R 7 , NR 6 COR 7 , SO 2 NR 6 R 7 and NR 6 SO 2 R 7 ;

or

R 10 and R 11 together with the nitrogen atom to which they are attached can form a 3-8 membered saturated heterocylic ring optionally containing one or more atoms selected from O, S(O) n (wherein n is 0, 1 or 2), NR 8 , and itself optionally substituted by halogen or C 1 -C 3 alkyl.

2. A compound according to claim 1 in which X is halogen, cyano, nitro, S(O) n R 6 or C 1-4 alkyl which is substituted by one or more halogen atoms.

3. A compound according to claim 1 in which X is trifluoromethyl, nitro, cyano or halogen.

4. A compound according to claim 1 in which Z is phenyl, which is substituted with one or more substituents as defined in claim 1 .

5. A compound according to claim 1 in which both R 1 and R 2 are hydrogen or one is hydrogen and the other is methyl or ethyl or both are methyl.

6. A compound according to claim 1 selected from:

{[5-Chloro-4′-(ethylthio)biphenyl-2-yl]oxy}acetic acid,

{[5-Chloro-4′-(ethylsulfonyl)biphenyl-2-yl]oxy}acetic acid,

[(4′,5-Dichlorobiphenyl-2-yl)oxy]acetic acid,

[(5-Chloro-4′-cyanobiphenyl-2-yl)oxy]acetic acid,

[(5-Chloro-4′-methoxybiphenyl-2-yl)oxy]acetic acid,

[(5-Chloro-3′,4′-dimethoxybiphenyl-2-yl)oxy]acetic acid,

2′-(Carboxymethoxy)-5′-chlorobiphenyl-4-carboxylic acid,

{[5-Chloro-4′-(methylsulfonyl)biphenyl-2-yl]oxy}acetic acid,

{[5-Chloro-4′-(ethylsulfonyl)-2′-methylbiphenyl-2-yl]oxy}acetic acid,

{[4′-(Methylthio)-5-(trifluoromethyl)biphenyl-2-yl]oxy}acetic acid,

{[4′-(Methylsulfonyl)-5-(trifluoromethyl)biphenyl-2-yl]oxy}acetic acid,

{[4′-(Ethylsulfonyl)-2′-methyl-5-(trifluoromethyl)biphenyl-2-yl]oxy}acetic acid,

[[2′,5-Dichloro-4′-(ethylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Chloro-4′-(ethylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5-Chloro-4′-(ethylsulfonyl)-2′-fluoro[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(Ethylsulfonyl)-2′-fluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5-Chloro-4′-(ethylsulfonyl)-2′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

2-[[5-Chloro-4′-(ethylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-propanoic acid,

2-[[4′-(Ethylsulfonyl)-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[4′-(Ethylsulfonyl)-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2R)-propanoic acid,

2-[[2′,5-Dichloro-4′-(ethylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-(25)-propanoic acid,

2-[[2′-Chloro-4′-(ethylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(25)-propanoic acid,

2-[[4′-(Ethylsulfonyl)-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-2-methyl-propanoic acid,

2-[[4′-(Ethylsulfonyl)-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-butanoic acid,

[[4′-(Ethylsulfonyl)-5-fluoro-2′-methyl[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(Ethylsulfonyl)-4,5-difluoro-2′-methyl[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(Ethylsulfonyl)-3,5-difluoro-2′-methyl[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Amino-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Amino-2′-chloro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Chloro-4′-hydroxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Chloro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′,5-Bis(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5′-Fluoro-2′-methoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5′-Cyano-2′-methoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Chloro-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′,5′-Dimethyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5′-Chloro-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Fluoro-6′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Fluoro-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[[(Ethylamino)carbonyl]amino]-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Methyl-4′-[[(methylamino)carbonyl]amino]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[[(Cyclopropylamino)carbonyl]amino]-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Methyl-4′-[[(propylamino)carbonyl]amino]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′,4′-Dimethyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5′-Fluoro-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(Aminocarbonyl)-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Fluoro-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′,5′-Difluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5′-(Aminosulfonyl)-2′-chloro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Cyano-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Chloro-2′-fluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′,5′-Difluoro-4′-methoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-fluoro-5′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Fluoro-4′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Methoxy-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(Aminosulfonyl)-2′,5′-difluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Chloro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-(1-Methylethyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′,4′-Difluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Ethyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Fluoro-5-(trifluoromethyl)[1,1′:4′,1″-terphenyl]-2-yl]oxy]acetic acid,

[[4′-(Trifluoromethoxy)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′,3′-Dichloro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(1,1-Dimethylethyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[2-(6-Methoxy-2-naphthalenyl)-4-(trifluoromethyl)phenoxy]-acetic acid,

[[4′-(Ethylthio)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Acetyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5′-(Aminosulfonyl)-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Cyano-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Methyl-5′-(methylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

2′-(Carboxymethoxy)-5′-(trifluoromethyl)-[1,1′-biphenyl]-3-carboxylic acid, 3-methyl ester,

2′-(Carboxymethoxy)-5′-(trifluoromethyl)-[1,1′-biphenyl]-2-carboxylic acid, 2-methyl ester,

[[5-(Trifluoromethyl)[1,1′:4′,1″-terphenyl]-2-yl]oxy]-acetic acid,

[[3′-Fluoro-2′,4′-dimethyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Nitro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Chloro-2′-methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5-(Trifluoromethyl)[1,1′:3′,1″-terphenyl]-2-yl]oxy]-acetic acid,

2′-(Carboxymethoxy)-5′-(trifluoromethyl)-[1,1′-biphenyl]-4-carboxylic acid, 4-methyl ester,

[[4′-Nitro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5-(Trifluoromethyl)-3′-[(trifluoromethyl)thio][1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[5-(Trifluoromethyl)-4′-[(trifluoromethyl)thio][1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Fluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Fluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Methyl-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Fluoro-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[2′-Methoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Methoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Methoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-(Ethylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[3′-Propoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-Propoxy-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[2-(2-Amino-4-methyl-5-pyrimidinyl)-4-(trifluoromethyl)phenoxy]-acetic acid,

[[4′-Cyano-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′,5-Bis(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[2-(2-Naphthalenyl)-4-(trifluoromethyl)phenoxy]-acetic acid,

[[4′-(1-Pyrrolidinylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[(Dimethylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[[(Phenylmethyl)amino]sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[[(2,2,2-Trifluoroethyl)amino]sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[[(5-Methyl-2-thiazolyl)amino]sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[(Phenylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[(Diethylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[(Cyclopropylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-(Aminosulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[(Methylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[[4′-[(4-Methyl-1-piperazinyl)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-acetic acid,

[2-[4-Methyl-2-(5-methyl-1,1-dioxido-1,2,5-thiadiazolidin-2-yl)-5-pyrimidinyl]-4-(trifluoromethyl)phenoxy]-acetic acid,

[[2′-Chloro-4′-[(methoxycarbonyl)amino]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]acetic acid

2-[[2′-Chloro-4′-(methylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[3′-Cyano-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[4′-[(Dimethylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[2′-Chloro-4′-[(dimethylamino)sulfonyl]-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[2′-Fluoro-4′-(methylsulfonyl)-5-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[2′,5-Dichloro-4′-(methylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[5-Chloro-4′-[(dimethylamino)sulfonyl][1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[2′,5-Dichloro-4′-[(dimethylamino)sulfonyl][1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[(5-Chloro-3′-cyano[1,1′-biphenyl]-2-yl)oxy]-(2S)-propanoic acid,

[[5-Chloro-4′-[(dimethylamino)sulfonyl]-2′-fluoro[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[5-Chloro-4′-(4-morpholinylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[5-Chloro-2′-fluoro-4′-(methylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[4′-(1-Azetidinylsulfonyl)-5-chloro[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[[5-Chloro-2′-methyl-4′-(1-pyrrolidinylcarbonyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[(2′,4′-Dichloro-5-cyano[1,1′-biphenyl]-2-yl)oxy]-(2S)-propanoic acid,

2-[[5-Cyano-2′-fluoro-4′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

2-[(3′-Cyano-5-fluoro[1,1′-biphenyl]-2-yl)oxy]-(2S)-propanoic acid, sodium salt,

2-[(2′,4′-Dichloro-5-fluoro[1,1′-biphenyl]-2-yl)oxy]-(2S)-propanoic acid, sodium salt,

2-[[2′-Chloro-5-fluoro-4′-(methylsulfonyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid

2-[[2′-Chloro-5-fluoro-5′-(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]-(2S)-propanoic acid,

[[4′-(Methylsulfonyl)-2′,5-bis(trifluoromethyl)[1,1′-biphenyl]-2-yl]oxy]acetic acid, and

[(5-Chloro-3′-cyano[1,1′-biphenyl]-2-yl)oxy]-acetic acid,

and pharmaceutically acceptable salts thereof.

7. A method of treating asthma or rhinitis in a patient suffering from, or at risk of, asthma or rhinitis, which comprises administering to the patient a therapeutically effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1 .

8. A compound according to claim 2 , in which Z is phenyl, which is substituted with one or more substituents as defined in claim 1 .

9. A compound according to claim 2 , in which both R 1 and R 2 are hydrogen or one is hydrogen and the other is methyl or ethyl or both are methyl.

10. A compound according to claim 3 , in which Z is phenyl, which is substituted with one or more substituents as defined in claim 1 .

11. A compound according to claim 3 , in which both R 1 and R 2 are hydrogen or one is hydrogen and the other is methyl or ethyl or both are methyl.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 7, 2006
From: BONNERT, ROGER; BROUGH, STEPHEN; DAVIES, ANDREW; LUKER, TIMOTHY; MCINALLY, THOMAS; MILLICHIP, IAN; PAIRAUDEAU, GARRY; PATEL, ANIL; RASUL, RUKHSANA; THOM, STEPHEN
To: ASTRAZENECA AB
Reel/Frame 017901/0053 →
Priority Claims (1)
SE 0301010 · Apr 7, 2003 · national
Continuity (1)
Related Publication 20060264435A1 · Nov 23, 2006